Ikarian Capital, LLC Aclaris Therapeutics, Inc. Transaction History

Ikarian Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.64 - $6.49 $12,468 - $126,438	19,482 New	19,482 $20,000
Q2 2023 Aug 14, 2023	SELL	$7.89 - $10.64 $789,000 - $1.06 Million	-100,000 Reduced 33.32%	200,163 $2.08 Million
Q1 2023 May 15, 2023	BUY	$7.07 - $17.95 $2.12 Million - $5.39 Million	300,163 New	300,163 $2.43 Million
Q2 2022 Aug 12, 2022	SELL	$10.16 - $17.08 $123,179 - $207,077	-12,124 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$9.74 - $17.92 $13,041 - $23,994	1,339 Added 12.42%	12,124 $208,000
Q4 2021 Feb 14, 2022	SELL	$12.27 - $18.49 $391,744 - $590,330	-31,927 Reduced 74.75%	10,785 $156,000
Q3 2021 Nov 15, 2021	SELL	$13.38 - $18.8 $629,876 - $885,028	-47,076 Reduced 52.43%	42,712 $770,000
Q2 2021 Aug 16, 2021	SELL	$17.08 - $29.6 $1.68 Million - $2.91 Million	-98,412 Reduced 52.29%	89,788 $1.58 Million
Q1 2021 May 17, 2021	SELL	$5.86 - $27.73 $655,148 - $3.1 Million	-111,800 Reduced 37.27%	188,200 $4.74 Million
Q4 2020 Feb 12, 2021	BUY	$2.65 - $7.61 $795,000 - $2.28 Million	300,000 New	300,000 $1.94 Million

52.4M

32.4K

3.3K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $139M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.